Singapore markets close in 4 hours 43 minutes

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
396.55-3.68 (-0.92%)
At close: 04:00PM EDT
396.20 -0.35 (-0.09%)
After hours: 07:50PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close400.23
Open396.57
Bid396.56 x 100
Ask396.77 x 100
Day's range393.76 - 400.14
52-week range316.43 - 448.40
Volume1,200,426
Avg. volume1,264,872
Market cap102.492B
Beta (5Y monthly)0.37
PE ratio (TTM)28.57
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex

    Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.

  • Yahoo Finance Video

    Vertex Pharmaceuticals to buy Alpine Immune Sciences in $4.9B deal

    Vertex Pharmaceuticals (VRTX) is set to acquire Alpine Immune Sciences (APLN) for $4.9 billion in cash, gaining access to Alpine's treatments for kidney disease. The deal from Vertex values Alpine's stock at $65 a share, which is a nearly 67% premium from the stock's close on Tuesday. Yahoo Finance Anchors Josh Lipton and Julie Hyman discuss the trend of "pipeline in a product" deals. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Nicholas Jacobino

  • Barrons.com

    Vertex Pharmaceuticals Seeks a Second Act With Alpine Immune Deal. What Wall Street Says.

    Vertex Pharmaceuticals is taking a big swing to secure its own second act: Late Wednesday, it announced a $4.9 billion deal to buy Alpine Immune Sciences which is developing a drug to treat a rare kidney disease. Vertex said it would pay $65 per share for Alpine, a 38.2% premium over the stock’s Wednesday closing price of $47.04. Shares of Alpine were trading at $64.19 early Thursday, while Vertex shares were up 1.2%.